{"name":"Mirna Therapeutics, Inc.","slug":"mirna-therapeutics-inc","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMixwFBVV95cUxNc2JXajQ2ejlMY0sxYnJUYWhEY0hhOE9uMGVreTlMR3hLbVJJRjFtMFNHR0R2elFkdjlkQ1RlS0NCV25KLU4yd3NVSi02UG5qSDRPZWJKZkt5SUtNUGJXX2hVenliRFVYWXdsRVRwdG5aLTZGOU5ZQjBkaUlhcGQtUjNyTXBHanpoVzlGajU4T0FFVFFMOEo0S3VwcEdUdEdvSXlyM0UzNG9IcllueWd5YXRjRGItVndYUTAySWVxRTZKQzJ1SHhR?oc=5","date":"2026-03-15","type":"pipeline","source":"AD HOC NEWS","summary":"Regulus Therapeutics Stock (ISIN: US7588491032) Faces Biotech Volatility Amid Pipeline Progress - AD HOC NEWS","headline":"Regulus Therapeutics Stock (ISIN: US7588491032) Faces Biotech Volatility Amid Pipeline Progress","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMizAFBVV95cUxPeVA1SWo1bjVPemRrdU03M0VZUlN1UzBQaVBWam5IMWVKOXZYOVc5ZEFDUUZoZ09fd1M3VTd2U1dPbW5ZZGNZN3pYb252bXUtdHNzdklGSlZOWHIwNmRYQ1JxUmV4SUt2V1VyejFkZXlQbVRSdmZEeDNHeDhQbXNmOGtFYUE4a2I4ZXV0VzR4TXhmLUU5eW1pSXhrU3BmN0dNRzh4M3ZnQ2dyNjdQVVdaaW02dDZXSnlCOXJvNWE3ODVmOXU0M0VTUE44M0Y?oc=5","date":"2025-09-18","type":"pipeline","source":"Business Wire","summary":"Neumirna Therapeutics Appoints Ellen K. Donnelly as Chief Executive Officer - Business Wire","headline":"Neumirna Therapeutics Appoints Ellen K. Donnelly as Chief Executive Officer","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiXEFVX3lxTE4yaTVZWmR0akJZcXNTOWRfeVZkMnpRbHNESEFwUEJNcENrYmtsX1Y1ZS1BYk8yV0t4VHBmVngxMGNmeGIwc09VSU5EdzVhaWxKSDZEV29LejlkTnIt?oc=5","date":"2025-09-16","type":"pipeline","source":"EurekAlert!","summary":"Targeted delivery of microRNA sponge short-hairpin RNA via VIR-inspired biotechnical vector: Enhancing cancer therapy - EurekAlert!","headline":"Targeted delivery of microRNA sponge short-hairpin RNA via VIR-inspired biotechnical vector: Enhancing cancer therapy - ","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMitwFBVV95cUxNM1lLaDFaaEt1TFZtdFpBdVNLRkFsTVlxR0xEX2VvSmFhVFB3dU40UXhDSTJ3cG5aYmMyUTZTbmJndXRGeW5pdDBRVnRHaUJzTUtveUVjYWU3UHNTd1JvMmV6ZVJKb2thODdSSHVGNDhxck9JVlJyRXQyY3lQalY3ZzA5MVo1UDFMWG9ZaWloMjJ5bWljVkZSRGNOYmplMVpWcTZJZVAyQ1VQNV93bnRESld4Z0NqWHc?oc=5","date":"2025-07-24","type":"deal","source":"The Ohio State University Wexner Medical Center","summary":"The Ohio State University Partners with Microlin Bio Inc. to Bring the University s Transformational Cancer Discoveries to Patients - The Ohio State University Wexner Medical Center","headline":"The Ohio State University Partners with Microlin Bio Inc. to Bring the University s Transformational Cancer Discoveries ","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMikgJBVV95cUxNdXowRi1CZncwcnVpQkFub1BSQmZPbVFzUjR0N3hVNE1FU1JNMzRLMmVEd011V1d6Z3lQemtELW9UVVNndlVYY1JhR3BzZEtldjZpckFyNnZTNFBPbUNveXRFU3ZNTUxuVHBhdXFrV1g4dDdzNGpBaHFmcTJvUjlFRE85MXpTdXlQZll3d18ySjVJNE9BYnRYNmtEdENLbkZoWmZKektWaDVCekRsbWtLM1FlMzh6RXkzOW1tSVJXaTFjT2lnV3FQbGJ0WHNOTS1jbHF0dGRubVZSWjZpYkl5VTlOVklOVmYwTWpNTDU4REloVTduTVZmdC1uYUVES0d1bjhCUUtxOG1zSklBSVg5Zm5n?oc=5","date":"2025-04-30","type":"deal","source":"Novartis","summary":"Novartis to acquire Regulus Therapeutics and farabursen, an investigational microRNA inhibitor to treat ADPKD, the most common genetic cause of renal failure - Novartis","headline":"Novartis to acquire Regulus Therapeutics and farabursen, an investigational microRNA inhibitor to treat ADPKD, the most ","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMingJBVV95cUxPTmZOaVNmTGdvLVVzYzNlcEljUlNUV2t2Y1Y2VWx6S3BVUVNjakZGOFlTT21uaHRZSnlxZWU5SGh1MndiQXRUUms3ZDUtSFVHcUFNQTU0WGRfbF9rUF95RjVNNUFMSVZDZGttWlN0SHlnNjI1aWc0VE5FZG9HYnRzUFZxaGd1d2hDb09RdEp0WmpxN1VvRWszMnRCRTZodmJqVkdpVC1zdF83ai1nalBsSWxWaXpnWGRhTmJVcmhKV3NvYlExdnB2b0ZQMVlfaUFrUmNkRllsVFU2LWR2Z3RIeWgyZVRyTDNrZHBXOFd0Y05NeVd4RFpHdkxFLXQtRXRPQ182VEFYUW9Jd3d3YTNrdzB1YVBydnB6QVc1cHp3?oc=5","date":"2025-04-09","type":"trial","source":"PR Newswire","summary":"NeuroSense Therapeutics Announces Transformative Phase 2b MicroRNA Data, Highlighting PrimeC's Promise as a Disease-Modifying ALS Treatment - PR Newswire","headline":"NeuroSense Therapeutics Announces Transformative Phase 2b MicroRNA Data, Highlighting PrimeC's Promise as a Disease-Modi","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiZEFVX3lxTE9FSXI1QkhDM3gzSUxydGR3MVduNUJVdGpiZ0kwbWVBdGtaQ28yaWJhX3k0d3hoQ183RUhtb3M1aTdLQzJKR2JGMFFyejRsUWl3bmFUZUtDSVVFMHh3bWprVHo4NHc?oc=5","date":"2024-11-26","type":"pipeline","source":"Labiotech.eu","summary":"Seven miRNA-focused companies pioneering new therapies in 2024 - Labiotech.eu","headline":"Seven miRNA-focused companies pioneering new therapies in 2024","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMirgFBVV95cUxNbkNubk8wbjFGS1FCRDRwTFVDc0s1T3M0M0Z2MDBWWF8wdmZkYVBNcDNmN202cDZFMWdFYkVoSTBDOTVtRVZnMnJGY3ZvcGgyOWhidmpldzRacXhuZnVTNmJYQkhXa0hMLXVnMndVWk5qZTFDU2c0RlctWGo3dEN4MjdINHQxZk9fYlkxcDU3VWRyRlJkdEZockZHWkFSSVFEbVVzVDZib0RkVU9nQnc?oc=5","date":"2024-09-10","type":"pipeline","source":"BioSpace","summary":"MicroRNA Market to Surge $6.11 Bn by 2034 Driven by Healthy 12.89% CAGR - BioSpace","headline":"MicroRNA Market to Surge $6.11 Bn by 2034 Driven by Healthy 12.89% CAGR","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiX0FVX3lxTE41NFlubFBiRzJfTzVJd2hRMXBOajJUemlHRHhWMkxpa0QyeVdpSTcyWTlidGNRQS14MTdCeFdtVHRDbVZRQ0dUYzNEaEdsNU1ic3ZQNm5HSDUzaGZTSGU4?oc=5","date":"2020-02-06","type":"pipeline","source":"nature.com","summary":"Screening of potential miRNA therapeutics for the prevention of multi-drug resistance in cancer cells | Scientific Reports - nature.com","headline":"Screening of potential miRNA therapeutics for the prevention of multi-drug resistance in cancer cells | Scientific Repor","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMinAFBVV95cUxQNmQtbWZEQnNscFBtWklqNGNQMzBYenludHc5RVlLa0k4X1EwTF9Cb19Mam9DYTlyZzJnM1hzVVpMWjFUc19RZVN0QUs0UFJoXzVsTXdlLW5ZUXRUQmxsZmxvM01OUThSSWNtaFB6OGp6UGV5ZFpQc1oxNVQxR3VTSml0MzRNWjlSSkhfQ3UtRzd2MTdsR2pjQ3JkQlI?oc=5","date":"2017-05-16","type":"deal","source":"BioPharma Dive","summary":"Synlogic goes public through merger with failed Mirna - BioPharma Dive","headline":"Synlogic goes public through merger with failed Mirna","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMioAFBVV95cUxNaUdGZ3hCMFpOR2N3OGw4dDdXejVvX0FBMm5tQ1Y2emxEVVJ0TDVHMEFibEp0WmREUU5hc2x0bXJfb3lfQ0RLWFJIbEtDbHdMWnNCQ1JjMkpLdnJjZHNoNGNzV2IwMUpyMHpzS1poRmVCM3EyWWRPcURLVWVkYmNmUG9iYU1LTVg4a25JQjFBaVM0TEhYSGswbjE1RXBraVhN?oc=5","date":"2016-09-21","type":"trial","source":"drugdiscoverytrends.com","summary":"Mirna Therapeutics Halts Phase 1 Clinical Study of Cancer Drug - drugdiscoverytrends.com","headline":"Mirna Therapeutics Halts Phase 1 Clinical Study of Cancer Drug","sentiment":"negative"},{"url":"https://news.google.com/rss/articles/CBMitgFBVV95cUxOdFczQ1N1dU1QT3ZScG5SbGxGNG82X2tmcEJXN2YwM1VDUnFXYzMyWVYxTXJZaUsxRlowZ0hHV0RIUHpLeExnbFRPMGFZZmpSNDY3WVdFdnE1VlE0d1ZpaldMZ1RfUEpza3F4MjZiZVZ1RklVVE1PR04xYnNXVy1Ram5VeVdBbHdsSkk4UDd0ajVxaVVSMl8zbGl1Y3pvVFdTTlJ5TDU3LXlfYTZiZjI2VGRKZU1TZw?oc=5","date":"2013-01-30","type":"pipeline","source":"Fierce Biotech","summary":"Mirna Therapeutics Inc. Appoints Clay B. Siegall, Ph.D., to Its Board of Directors - Fierce Biotech","headline":"Mirna Therapeutics Inc. Appoints Clay B. Siegall, Ph.D., to Its Board of Directors","sentiment":"neutral"}],"patents":[],"drugCount":0,"phaseCounts":{},"enrichmentLevel":2,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}